Novel Targeted Therapies in Inflammatory Breast CancerCRISTOFANILLI, Massimo.Cancer. 2010, Vol 116, Num 11, pp 2837-2839, issn 0008-543X, 3 p., SUPConference Paper

The Medical Treatment of Inflammatory Breast CancerDAWOOD, Shaheenah; UENO, Naoto T; CRISTOFANILLI, Massimo et al.Seminars in oncology. 2008, Vol 35, Num 1, pp 64-71, issn 0093-7754, 8 p.Article

Pathologic Aspects of Inflammatory Breast Carcinoma. Part 1. Histomorphology and Differential DiagnosisRESETKOVA, Erika.Seminars in oncology. 2008, Vol 35, Num 1, pp 25-32, issn 0093-7754, 8 p.Article

Surgical Management of Inflammatory Breast CancerSINGLETARY, S. Eva.Seminars in oncology. 2008, Vol 35, Num 1, pp 72-77, issn 0093-7754, 6 p.Article

Pathologic Aspects of Inflammatory Breast Cancer. Part 2. Biologic Insights Into Its Aggressive PhenotypeYUN GONG.Seminars in oncology. 2008, Vol 35, Num 1, pp 33-40, issn 0093-7754, 8 p.Article

Inflammatory Breast Cancer : Patient Advocate ViewMASON, Ginny; JOHNSON, Owen.Seminars in oncology. 2008, Vol 35, Num 1, pp 87-91, issn 0093-7754, 5 p.Article

Circulating tumor cells, disease progression, and survival in metastatic breast cancerCRISTOFANILLI, Massimo.Seminars in oncology. 2006, Vol 33, Num 3, issn 0093-7754, S9-S14, SUP9Article

Systemic treatments for inflammatory breast cancerYANG, Charles H; CRISTOFANILLI, Massimo.Breast disease. 2005, Vol 22, pp 55-65, issn 0888-6008, 11 p.Article

Evolving Role of Imaging Modalities in Inflammatory Breast CancerLE-PETROSS, Carisa H; BIDAUT, Luc; YANG, Wei T et al.Seminars in oncology. 2008, Vol 35, Num 1, pp 51-63, issn 0093-7754, 13 p.Article

Circulating Tumor DNA to Monitor Metastatic Breast CancerCRISTOFANILLI, Massimo; FORTINA, Paolo; WEISS, Lukas et al.The New England journal of medicine. 2013, Vol 369, Num 1, pp 93-94, issn 0028-4793, 2 p.Article

New generation of molecular prognostic and predictive tests for breast cancerPUSZTAI, Lajos; CRISTOFANILLI, Massimo; PAIK, Soonmyung et al.Seminars in oncology. 2007, Vol 34, Num 2, issn 0093-7754, S10-S16, SUP3Conference Paper

Dyadic Coping in Metastatic Breast CancerBADR, Hoda; CARMACK, Cindy L; KASHY, Deborah A et al.Health psychology (Hillsdale, N.J.). 2010, Vol 29, Num 2, pp 169-180, issn 0278-6133, 12 p.Article

Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast CancerBOUSSEN, Hamouda; CRISTOFANILLI, Massimo; ZAKS, Tal et al.Journal of clinical oncology. 2010, Vol 28, Num 20, pp 3248-3255, issn 0732-183X, 8 p.Article

Differences in Survival Among Women With Stage III Inflammatory and Noninflammatory Locally Advanced Breast Cancer Appear Early: A Large Population-Based StudyDAWOOD, Shaheenah; UENO, Naoto T; VALERO, Vicente et al.Cancer. 2011, Vol 117, Num 9, pp 1819-1826, issn 0008-543X, 8 p.Article

Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24^lo cancer stem cell phenotypeREUBEN, James M; LEE, Bang-Ning; CRISTOFANILLI, Massimo et al.European journal of cancer (1990). 2011, Vol 47, Num 10, pp 1527-1536, issn 0959-8049, 10 p.Article

Polycomb Group Protein EZH2 Is Frequently Expressed in Inflammatory Breast Cancer and Is Predictive of Worse Clinical OutcomeYUN GONG; LEI HUO; PING LIU et al.Cancer. 2011, Vol 117, Num 24, pp 5476-5484, issn 0008-543X, 9 p.Article

Prognostic Value of Body Mass Index in Locally Advanced Breast CancerDAWOOD, Shaheenah; BROGLIO, Kristine; GONZALEZ-ANGULO, Ana M et al.Clinical cancer research. 2008, Vol 14, Num 6, pp 1718-1725, issn 1078-0432, 8 p.Article

Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast CancerMOULDER, Stacy L; FRASER SYMMANS, W; ZWIEBEL, James et al.Clinical cancer research (Print). 2008, Vol 14, Num 23, pp 7909-7916, issn 1078-0432, 8 p.Article

A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer : Safety, efficacy, and biologic activity of a novel gene-therapy approachCRISTOFANILLI, Massimo; KRISHNAMURTHY, Savitri; GUERRA, Laura et al.Cancer. 2006, Vol 107, Num 5, pp 935-944, issn 0008-543X, 10 p.Article

Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapyHENNESSY, Bryan T; GONZALEZ-ANGULO, Ana Maria; VALERO, Vicente et al.Cancer. 2006, Vol 106, Num 5, pp 1000-1006, issn 0008-543X, 7 p.Article

Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrenceSHEN, Jeannie; HUNT, Kelly K; EVA SINGLETARY, S et al.Cancer. 2005, Vol 104, Num 3, pp 479-490, issn 0008-543X, 12 p.Article

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancerESTEVA, Francisco J; VALERO, Vicente; SNEIGE, Nour et al.Journal of clinical oncology. 2002, Vol 20, Num 7, pp 1800-1808, issn 0732-183XArticle

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationSEIDMAN, Andrew D; FORNIER, Monica N; GILEWSKI, Teresa et al.Journal of clinical oncology. 2001, Vol 19, Num 10, pp 2587-2595, issn 0732-183XArticle

Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast CancerJESELSOHN, Rinath; YELENSKY, Roman; ARTEAGA, Carlos L et al.Clinical cancer research (Print). 2014, Vol 20, Num 7, pp 1757-1767, issn 1078-0432, 11 p.Article

A Phase 1 Study of Weekly Everolimus (RAD001) in Combination With Docetaxel in Patients With Metastatic Breast CancerMOULDER, Stacy; GLADISH, Gregory; RIVERA, Edgardo et al.Cancer. 2012, Vol 118, Num 9, pp 2378-2384, issn 0008-543X, 7 p.Article